Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
© 2020 Elsevier B.V. Background: Dapagliflozin is an antidiabetic medication that has been shown to reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to determine the cost-utility of add-o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Journal |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089826614&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Chiang Mai University |